Grants per year
Grants
- 13 Active
Search results
-
Active
Prot #CAAA617C12301: PSMAddition: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination with Standard of Care, Versus Standard of Care Alone, in Adult Male Patients with Metastatic Hormone Sensitive P
Novartis Pharmaceuticals Corporation
2/9/22 → 11/21/25
Project: Research project
-
North American Star Consortium
Mahalingam, D., Sosman, J. A., Sosman, J. A., Kumthekar, P. U. & VanderWeele, D. J.
University Health Network (Toronto), National Cancer Institute
3/1/20 → 2/28/26
Project: Research project
-
Prot #PCCTC #: c17‐191: CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone, A Phase II Study of Carboplatin, Cabazitaxel and Abiraterone in Metastatic Castration Sensitive Prostate Cancer with and without DNA Repair Mutations
Prostate Cancer Clinical Trials Consortium, LLC, Genzyme Corporation
2/28/20 → 2/28/23
Project: Research project
-
Prot #D933RC00001: A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for Adjuvant Treatment i
AstraZeneca Pharmaceuticals LP
11/20/19 → 11/20/22
Project: Research project
-
Prot #D933SC00001: A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Ver
AstraZeneca Pharmaceuticals LP
7/22/19 → 7/22/22
Project: Research project